

PROVIDER NOTIFICATION OF RETAIL DRUG POLICY CRITERIA CHANGE			
Drug Impacted	CRITERIA CHANGE	EFFECTIVE DATE	Formulary
Empaveli	Added prescriber specialty for complement 3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). Updated criteria for C3G that laboratory values (proteinuria or UPCR) be obtained within 3 months prior to the initiation of the requested medication.	3/31/2026	Essential
Zejula	Added requirement for prostate cancer that member has not progressed on prior novel hormone therapy per NCCN.	4/1/2026	Standard, Essential and Metallic